SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
People carry mock coffins in front of British Prime Minister Boris Johnson's office in London on October 12, 2021. (Photo: Hasan Esen/Anadolu Agency via Getty Images)
Corruption in Drug Patents: Take Away the Money
When patents can be worth enormous sums of money, companies will find ways to abuse the system.
Apr 18, 2022
The New York Times had an editorial about the corruption of the patent system in recent decades. It noted that the patent office is clearly not following the legal standards for issuing a patent, including that the item being patented is a genuine innovation and that it works. Among other things, it pointed out that Theranos had been issued dozens of patents for a technique that clearly did not work.
As the editorial notes, the worst patent abuses occur with prescription drugs. Drug companies routinely garner dozens of dubious patents for their leading sellers, making it extremely expensive for potential generic competitors to enter the market. The piece points out that the twelve drugs that get the most money from Medicare have an average of more than fifty patents each.
The piece suggests some useful reforms, but it misses the fundamental problem. When patents can be worth enormous sums of money, companies will find ways to abuse the system.
We need to understand the basic principle here. Patents are a government intervention in the free market, they impose a monopoly in a particular market.
We should think of patents like price controls under the Soviet system of central planning. This system routinely led to shortages in many areas. As a result, there was a huge black market. Well-positioned individuals pulled items like blue jeans or milk, or other consumer products out of the official system and sold them for a huge premium on the black market.
The Soviet Union responded by getting more police and imposing harsher penalties for black market trades, but the standard economist solution was to take the money away. By that we mean stop regulating prices, let the market determine the price. When that happens, there is no room for a black market.
We should think about patents in the same way. While patents can be a useful tool for promoting innovation, when huge sums are available by claiming a patent, we should expect there will be corruption, in spite of our best efforts to constrain it. This means that we should limit their use and try to ensure that we only rely on them where patent monopolies are clearly the best mechanism to promote innovation.
I have argued that we should rely on publicly funded research, rather than patent monopolies when it comes to prescription drugs and medical equipment. In addition to promoting corruption, these monopolies create the absurd situation where many lifesaving drugs that would sell in a free market for twenty or thirty dollars, instead sell for thousands or even tens of thousands of dollars. (Solvaldi, a breakthrough drug for treating Hepatitis C, sold here for $84,000 for a three-month course of treatment. A high-quality generic version was available in India for $300.)
The situation is made even worse by the fact that we typically have third party payers. This means that patients needing treatment have to persuade a government bureaucracy or private insurer to pay for an expensive drug that would cost just a few dollars in a free market.
The abuses are less severe in other areas, but we should be looking to reduce the value of patents (and copyrights) everywhere, and rely on alternative mechanisms for supporting innovation. I discuss alternatives in chapter 5 of Rigged (it's free).
It's great to see the New York Times recognize the abuses of the patent system. It would be even better if it opened its pages to discussion of alternative mechanisms for financing innovation.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
This work is licensed under a Creative Commons Attribution 4.0 International License
Dean Baker
Dean Baker is the co-founder and the senior economist of the Center for Economic and Policy Research (CEPR). He is the author of several books, including "Getting Back to Full Employment: A Better bargain for Working People," "The End of Loser Liberalism: Making Markets Progressive," "The United States Since 1980," "Social Security: The Phony Crisis" (with Mark Weisbrot), and "The Conservative Nanny State: How the Wealthy Use the Government to Stay Rich and Get Richer." He also has a blog, "Beat the Press," where he discusses the media's coverage of economic issues.
The New York Times had an editorial about the corruption of the patent system in recent decades. It noted that the patent office is clearly not following the legal standards for issuing a patent, including that the item being patented is a genuine innovation and that it works. Among other things, it pointed out that Theranos had been issued dozens of patents for a technique that clearly did not work.
As the editorial notes, the worst patent abuses occur with prescription drugs. Drug companies routinely garner dozens of dubious patents for their leading sellers, making it extremely expensive for potential generic competitors to enter the market. The piece points out that the twelve drugs that get the most money from Medicare have an average of more than fifty patents each.
The piece suggests some useful reforms, but it misses the fundamental problem. When patents can be worth enormous sums of money, companies will find ways to abuse the system.
We need to understand the basic principle here. Patents are a government intervention in the free market, they impose a monopoly in a particular market.
We should think of patents like price controls under the Soviet system of central planning. This system routinely led to shortages in many areas. As a result, there was a huge black market. Well-positioned individuals pulled items like blue jeans or milk, or other consumer products out of the official system and sold them for a huge premium on the black market.
The Soviet Union responded by getting more police and imposing harsher penalties for black market trades, but the standard economist solution was to take the money away. By that we mean stop regulating prices, let the market determine the price. When that happens, there is no room for a black market.
We should think about patents in the same way. While patents can be a useful tool for promoting innovation, when huge sums are available by claiming a patent, we should expect there will be corruption, in spite of our best efforts to constrain it. This means that we should limit their use and try to ensure that we only rely on them where patent monopolies are clearly the best mechanism to promote innovation.
I have argued that we should rely on publicly funded research, rather than patent monopolies when it comes to prescription drugs and medical equipment. In addition to promoting corruption, these monopolies create the absurd situation where many lifesaving drugs that would sell in a free market for twenty or thirty dollars, instead sell for thousands or even tens of thousands of dollars. (Solvaldi, a breakthrough drug for treating Hepatitis C, sold here for $84,000 for a three-month course of treatment. A high-quality generic version was available in India for $300.)
The situation is made even worse by the fact that we typically have third party payers. This means that patients needing treatment have to persuade a government bureaucracy or private insurer to pay for an expensive drug that would cost just a few dollars in a free market.
The abuses are less severe in other areas, but we should be looking to reduce the value of patents (and copyrights) everywhere, and rely on alternative mechanisms for supporting innovation. I discuss alternatives in chapter 5 of Rigged (it's free).
It's great to see the New York Times recognize the abuses of the patent system. It would be even better if it opened its pages to discussion of alternative mechanisms for financing innovation.
Dean Baker
Dean Baker is the co-founder and the senior economist of the Center for Economic and Policy Research (CEPR). He is the author of several books, including "Getting Back to Full Employment: A Better bargain for Working People," "The End of Loser Liberalism: Making Markets Progressive," "The United States Since 1980," "Social Security: The Phony Crisis" (with Mark Weisbrot), and "The Conservative Nanny State: How the Wealthy Use the Government to Stay Rich and Get Richer." He also has a blog, "Beat the Press," where he discusses the media's coverage of economic issues.
The New York Times had an editorial about the corruption of the patent system in recent decades. It noted that the patent office is clearly not following the legal standards for issuing a patent, including that the item being patented is a genuine innovation and that it works. Among other things, it pointed out that Theranos had been issued dozens of patents for a technique that clearly did not work.
As the editorial notes, the worst patent abuses occur with prescription drugs. Drug companies routinely garner dozens of dubious patents for their leading sellers, making it extremely expensive for potential generic competitors to enter the market. The piece points out that the twelve drugs that get the most money from Medicare have an average of more than fifty patents each.
The piece suggests some useful reforms, but it misses the fundamental problem. When patents can be worth enormous sums of money, companies will find ways to abuse the system.
We need to understand the basic principle here. Patents are a government intervention in the free market, they impose a monopoly in a particular market.
We should think of patents like price controls under the Soviet system of central planning. This system routinely led to shortages in many areas. As a result, there was a huge black market. Well-positioned individuals pulled items like blue jeans or milk, or other consumer products out of the official system and sold them for a huge premium on the black market.
The Soviet Union responded by getting more police and imposing harsher penalties for black market trades, but the standard economist solution was to take the money away. By that we mean stop regulating prices, let the market determine the price. When that happens, there is no room for a black market.
We should think about patents in the same way. While patents can be a useful tool for promoting innovation, when huge sums are available by claiming a patent, we should expect there will be corruption, in spite of our best efforts to constrain it. This means that we should limit their use and try to ensure that we only rely on them where patent monopolies are clearly the best mechanism to promote innovation.
I have argued that we should rely on publicly funded research, rather than patent monopolies when it comes to prescription drugs and medical equipment. In addition to promoting corruption, these monopolies create the absurd situation where many lifesaving drugs that would sell in a free market for twenty or thirty dollars, instead sell for thousands or even tens of thousands of dollars. (Solvaldi, a breakthrough drug for treating Hepatitis C, sold here for $84,000 for a three-month course of treatment. A high-quality generic version was available in India for $300.)
The situation is made even worse by the fact that we typically have third party payers. This means that patients needing treatment have to persuade a government bureaucracy or private insurer to pay for an expensive drug that would cost just a few dollars in a free market.
The abuses are less severe in other areas, but we should be looking to reduce the value of patents (and copyrights) everywhere, and rely on alternative mechanisms for supporting innovation. I discuss alternatives in chapter 5 of Rigged (it's free).
It's great to see the New York Times recognize the abuses of the patent system. It would be even better if it opened its pages to discussion of alternative mechanisms for financing innovation.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.